Outcome of Board Meeting on 28.05.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved audited standalone and consolidated financial results for Q4 and FY25 (year ended 31 March 2025) with an unmodified auditor's opinion. On a standalone basis, revenue from operations more than doubled to Rs. 2,490.61 lakh (vs Rs. 1,201.67 lakh in FY24, ~107% growth), while profit after tax rose ~72% to Rs. 308.81 lakh and EPS stood at Rs. 6.71. On a consolidated basis, revenue was largely flat at Rs. 3,480.81 lakh, but PAT grew ~48% to Rs. 404.61 lakh with EPS of Rs. 8.80. The Board recommended a 10% dividend (Re. 1 per share) subject to shareholder approval, approved grant of 23,000 ESOPs, and proposed issue of up to 2,41,000 convertible warrants on a preferential basis to promoter group entity M/s. Aura Alkalies and Chemicals Pvt Ltd. M/s. Jay Mehta & Associates was appointed as Secretarial Auditor for five years (FY26–FY30).
Strong standalone earnings growth and a dividend declaration are positive for shareholders, while the warrant issue to the promoter entity signals potential equity dilution if converted. Negative operating cash flows on both standalone (Rs. -340.64 lakh) and consolidated (Rs. -461.61 lakh) bases are a watchpoint despite healthy reported profits.